UoGlasgow Confidence in Concept 2013
Lead Research Organisation:
University of Glasgow
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
Publications
Abraham SA
(2016)
Casting a NETwork instead of shooting magic bullets.
in Cell cycle (Georgetown, Tex.)
Abraham SA
(2016)
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.
in Nature
Al-Riyami L
(2015)
Protective effect of small molecule analogues of the Acanthocheilonema viteae secreted product ES-62 on oxazolone-induced ear inflammation.
in Experimental parasitology
Baillie GS
(2019)
Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.
in Nature reviews. Drug discovery
Blair CM
(2019)
Reshaping cAMP nanodomains through targeted disruption of compartmentalised phosphodiesterase signalosomes.
in Biochemical Society transactions
Blair CM
(2019)
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
in BMC cancer
Clarke CJ
(2017)
Preclinical approaches in chronic myeloid leukemia: from cells to systems.
in Experimental hematology
Coltherd JC
(2016)
The parasitic worm-derived immunomodulator, ES-62 and its drug-like small molecule analogues exhibit therapeutic potential in a model of chronic asthma.
in Scientific reports
Cuschieri K
(2021)
Penile cancer and the HPV attributable fraction in Scotland; A retrospective cohort study.
in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Doonan J
(2018)
Protection Against Arthritis by the Parasitic Worm Product ES-62, and Its Drug-Like Small Molecule Analogues, Is Associated With Inhibition of Osteoclastogenesis
in Frontiers in Immunology
| Description | New technique training to research technician |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | The work has fed into development of a clinical trial grant application to CRUK-EMP |
| Description | BHF Project Grant |
| Amount | £251,755 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 08/2020 |
| Description | Biomedical Catalyst Feasibility |
| Amount | £70,000 (GBP) |
| Funding ID | Application Number: 81103-511295 |
| Organisation | MRC Biomedical Catalyst Developmental Pathway Funding Scheme (DPFS) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 04/2018 |
| Description | Biomedical Catalyst: Developmental Pathway Funding Scheme (DPFS) |
| Amount | £1,258,477 (GBP) |
| Funding ID | MR/N018958/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2016 |
| End | 04/2019 |
| Description | Collaborative Award |
| Amount | £2,151,302 (GBP) |
| Funding ID | 201505/Z/16/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 07/2021 |
| Description | Collaborative research funding. |
| Amount | £6,000 (GBP) |
| Organisation | Constellation Pharmaceuticals |
| Sector | Private |
| Country | United States |
| Start | 11/2014 |
| End | 10/2015 |
| Description | Collaborative research grant |
| Amount | £32,000 (GBP) |
| Organisation | Roche Pharmaceuticals |
| Sector | Private |
| Country | Global |
| Start | 11/2014 |
| End | 10/2015 |
| Description | ERC Advanced Grant |
| Amount | € 3,093,480 (EUR) |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 09/2017 |
| End | 08/2022 |
| Description | Grant - Research |
| Amount | £307,675 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2016 |
| End | 01/2019 |
| Description | Grant - Research |
| Amount | £115,988 (GBP) |
| Organisation | Versus Arthritis |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 03/2018 |
| Description | High-Growth Spinout Programme |
| Amount | £394,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 11/2018 |
| Description | MRC iCASE |
| Amount | £112,164 (GBP) |
| Funding ID | MR/N018230/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2020 |
| Description | MRC project grant |
| Amount | £595,086 (GBP) |
| Funding ID | MR/N011112/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2016 |
| End | 04/2019 |
| Description | MRC/CiC |
| Amount | £23,540 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2014 |
| End | 09/2015 |
| Description | MRS studentship |
| Amount | £125,000 (GBP) |
| Funding ID | PhD-890-2015 |
| Organisation | Medical Research Scotland |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2020 |
| Description | Medical Research Scotland PhD studentship |
| Amount | £116,308 (GBP) |
| Funding ID | PhD-789-2014 |
| Organisation | Medical Research Scotland |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 09/2019 |
| Description | Programme grant |
| Amount | £1,700,000 (GBP) |
| Funding ID | Award No. 14033 |
| Organisation | Leukaemia and Lymphoma Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2015 |
| End | 05/2020 |
| Description | Researcher Initiated Grant Scheme |
| Amount | £279,195 (GBP) |
| Organisation | Chief Scientist Office |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 02/2021 |
| Description | SULSA Hi-Throughput assay development fund. |
| Amount | £3,000 (GBP) |
| Organisation | Scottish Universities Life Sciences Alliance |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 05/2015 |
| Description | UK Biomedical Catalyst |
| Amount | £198,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2017 |
| End | 07/2018 |
| Title | 3D model |
| Description | We have been developing a 3D culture system that will be further developed as a model system for human joints in arthritis by MAP in his ARUK-CDF |
| Type Of Material | Model of mechanisms or symptoms - in vitro |
| Provided To Others? | No |
| Impact | By developing an in vitro model of mouse and human arthritic joints, this will allow us to screen a large number of SMAs in vitro, obviating the need for a large number of the animal models that we require at present |
| Title | New in-vivo approaches in xenograft mouse model |
| Description | Ability to administrate small molecules to sub-lethally irradiated NSG mice |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | Set a new level of optimisation for CML in NSG mice |
| Title | stemformatics |
| Description | stem cell data including leukaemia stem cells |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | Publication in Nature and Cancer Discovery and lots of press release around this |
| Description | Clinical consortium |
| Organisation | NHS Greater Glasgow and Clyde (NHSGGC) |
| Department | Beatson West of Scotland Cancer Centre |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | In 2021 we forged a new clinical consortium consisting of oncologists, pathologists, epidemiologists, clinical scientists and statisticians to take forward clinical HPV research in the West of Scotland. It is led by Dr Kathryn Graham, Consultant Oncologist, Beatson cancer Centre, NHS GGC. I am the basic scientist on this consortium. |
| Collaborator Contribution | The partners offer different expertise to the project, oncology, pathology, clinical testing, surgery. |
| Impact | University of Glasgow MRC Confidence in Concept award £80,000 "BioMARSC: RNA Biomarker Matrix for Risk Stratification of Cervical Disease". |
| Start Year | 2021 |
| Description | SHINe |
| Organisation | University of Edinburgh |
| Department | Scottish HPV Investigators Network (SHINe) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I am a member of this consortium |
| Collaborator Contribution | Discussions, clinical material, new projects initiated |
| Impact | Funding for an MRC Clinical Training Fellow. Two papers in submission. A grant application in preparation |
| Start Year | 2009 |
| Description | miR96 and pulmonary hypertension |
| Organisation | United Therapeutics |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Building on our success with the MRC CiC award and the PhD studentship we were awarded a MRC project grant to further our studies into miR96 and PAH. This created discussions with United Therapeutics who supplemented tis study. |
| Collaborator Contribution | Provision of £79000 to cover costs of a patent and RNAseq |
| Impact | Too early |
| Start Year | 2016 |
| Title | ???????????????? |
| Description | The invention relates to the use of microRNA 96 and precursors and mimics thereof for the inhibition of vascular cell proliferation and/or vascular remodelling, and for the treatment of associated medical conditions such as pulmonary arterial hypertension (PAH). |
| IP Reference | CN106029887 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | ????????????????????? |
| Description | ?????????????/?????????????????????????????????????????(PAH)????????????RNA96??????????????????????????? |
| IP Reference | JP2016540049 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | COLICINS FOR TREATING BACTERIAL INFECTIONS |
| Description | The Invention relates to materials and methods for the treatment of conditions associated with bacterial biofilms, intracellular bacterial infections and/or adherent-invasive Escherichia coli infections, including Crohns' disease. In particular, the invention relates to the use of colicins and bacteria producing colicins, for the treatment of such conditions. |
| IP Reference | GB20120012588 |
| Protection | Patent application published |
| Year Protection Granted | 2013 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | COLICINS FOR TREATING BACTERIAL INFECTIONS |
| Description | The Invention relates to materials and methods for the treatment of conditions associated with bacterial biofilms, intracellular bacterial infections and/or adherent-invasive Escherichia coli infections, including Crohns' disease. In particular, the invention relates to the use of colicins and bacteria producing colicins, for the treatment of such conditions. |
| IP Reference | US2019151408 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | COLICINS FOR TREATING BACTERIAL INFECTIONS |
| Description | The Invention relates to materials and methods for the treatment of conditions associated with bacterial biofilms, intracellular bacterial infections and/or adherent-invasive Escherichia coli infections, including Crohns' disease. In particular,, the invention relates to the use of colicins and bacteria producing colicins, for the treatment of such conditions. |
| IP Reference | CA2878890 |
| Protection | Patent application published |
| Year Protection Granted | 2014 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | COLICINS FOR TREATING BACTERIAL INFECTIONS |
| Description | The Invention relates to materials and methods for the treatment of conditions associated with bacterial biofilms, intracellular bacterial infections and/or adherent-invasive Escherichia coli infections, including Crohns' disease. In particular,, the invention relates to the use of colicins and bacteria producing colicins, for the treatment of such conditions. |
| IP Reference | EP2872162 |
| Protection | Patent granted |
| Year Protection Granted | 2015 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | Colicins for treating bacterial infections |
| Description | The Invention relates to materials and methods for the treatment of conditions associated with bacterial biofilms, intracellular bacterial infections and/or adherent-invasive Escherichia coli infections, including Crohns' disease. In particular,, the invention relates to the use of colicins and bacteria producing colicins, for the treatment of such conditions. |
| IP Reference | AU2013288416 |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | IMMUNOMODULATORY COMPOUNDS |
| Description | This invention relates to compounds and uses thereof in the treatment or prophylaxis of diseases associated with inflammation |
| IP Reference | GB1214106.5 |
| Protection | Patent application published |
| Year Protection Granted | 2014 |
| Licensed | No |
| Impact | In development |
| Title | IMMUNOMODULATORY COMPOUNDS |
| Description | This invention relates to compounds and uses thereof in the treatment or prophylaxis of diseases associated with inflammation. |
| IP Reference | EP2882727 |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | In development |
| Title | IMMUNOMODULATORY COMPOUNDS |
| Description | This invention relates to compounds and uses thereof in the treatment or prophylaxis of diseases associated with inflammation. |
| IP Reference | WO2014023934 |
| Protection | Patent application published |
| Year Protection Granted | 2014 |
| Licensed | No |
| Impact | This has now been published in the European (17.06.2015) and USA patent offices (06.08.2015) allowing the therapeutic potential of our SMAs to be evaluated in several indications in partnership with Industry: in particular with Jubilant- India (matched funding from the University of Strathclyde) in Lung Fibrosis, AstraZeneca in Alopecia and Leopharma in Psoriasis. |
| Title | Immunomodulatory Compounds |
| Description | This invention relates to compounds and uses thereof in the treatment or prophylaxis of diseases associated with inflammation. |
| IP Reference | US2015218116 |
| Protection | Patent granted |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | In development |
| Title | MATERIALS AND METHODS FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
| Description | The invention relates to the use of microRNA 96 and precursors and mimics thereof for the inhibition of vascular cell proliferation and/or vascular remodelling, and for the treatment of associated medical conditions such as pulmonary arterial hypertension (PAH). |
| IP Reference | GB20140016570 |
| Protection | Patent application published |
| Year Protection Granted | 2014 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | MATERIALS AND METHODS FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
| Description | The invention relates to the use of microRNA 96 and precursors and mimics thereof for the inhibition of vascular cell proliferation and/or vascular remodelling, and for the treatment of associated medical conditions such as pulmonary arterial hypertension (PAH). |
| IP Reference | CA2932035 |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | MATERIALS AND METHODS FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
| Description | The invention relates to the use of microRNA 96 and precursors and mimics thereof for the inhibition of vascular cell proliferation and/or vascular remodelling, and for the treatment of associated medical conditions such as pulmonary arterial hypertension (PAH). |
| IP Reference | EP3077509 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | MATERIALS AND METHODS FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
| Description | The invention relates to the use of microRNA 96 and precursors and mimics thereof for the inhibition of vascular cell proliferation and/or vascular remodelling, and for the treatment of associated medical conditions such as pulmonary arterial hypertension (PAH). |
| IP Reference | GB20130021237 |
| Protection | Patent application published |
| Year Protection Granted | 2013 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | MATERIALS AND METHODS FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
| Description | The invention relates to the use of microRNA 96 and precursors and mimics thereof for the inhibition of vascular cell proliferation and/or vascular remodelling, and for the treatment of associated medical conditions such as pulmonary arterial hypertension (PAH). |
| IP Reference | WO2015082896 |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | Materials and Methods for Treatment of Pulmonary Arterial Hypertension |
| Description | The invention relates to the use of microRNA 96 and precursors and mimics thereof for the inhibition of vascular cell proliferation and/or vascular remodelling, and for the treatment of associated medical conditions such as pulmonary arterial hypertension (PAH). |
| IP Reference | US2016304869 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | too early |
| Title | PULMONARY ADMINISTRATION OF PYOCINS FOR TREATING BACTERIAL RESPIRATORY INFECTIONS |
| Description | The invention relates to the treatment of bacterial respiratory infections using the bacterially-originating antibiotics known as pyocins. In particular, the invention provides the use of S-type pyocins, administered by pulmonary administration, for the treatment of such infections. |
| IP Reference | WO2016046218 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | Also published as: GB20140016788 (UK), CA2962117 (Canada), CN107073073 (China), EP3200813 (Europe), JP2017529398 (Japan), US2017240602 (UsS |
| Title | Idasanutlin |
| Description | submitting clinical trIal grant CRUK EMP 20 March |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2017 |
| Development Status | Actively seeking support |
| Impact | NOT YET |
| Company Name | PROTOBIOTIX LIMITED |
| Description | for development of novel therapeutics |
| Year Established | 2018 |
| Impact | none yet |
| Description | British Heart Foundation Rock up in Red Day |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Supporters |
| Results and Impact | As part of Rock up in Red events the Institute hosted an open day for BHF fundraisers and shop workers. We hosted a coffee morning to chat to them about research and show them where the money from fund raising is invested and gave them tours of the building. |
| Year(s) Of Engagement Activity | 2015 |
| Description | EHA, Vienna |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Speaking at European Haematology Association Meeting in Vienna |
| Year(s) Of Engagement Activity | 2015 |
| Description | ESH Portugal |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Health professionals |
| Results and Impact | Talk with discussion improved collaborations |
| Year(s) Of Engagement Activity | 2013 |
| Description | ESH, Estoril |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Keynote Lecturer at the European Society of Haematology, Estoril, Portugal |
| Year(s) Of Engagement Activity | 2015 |
| Description | Hinterzarten Circle on Cancer Research, Italy |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Speaking at annual meeting of the Hinterzarten Circle on Cancer Research of the DFG (German Research Foundation |
| Year(s) Of Engagement Activity | 2015 |
| Description | Hosting local BHF Fundraising team |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Supporters |
| Results and Impact | Hosted visits to the Institute of local BHF fundraising team, patients/ donors |
| Year(s) Of Engagement Activity | 2017 |
| Description | Institute Open Day |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Our Institute hosted an open day to showcase ongoing research. I also took part in round table debates with pupils on different aspects of research and judged the "best scientific question" competiion |
| Year(s) Of Engagement Activity | 2015 |
| Description | Keynote lecture |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Keynote lecture - Course on Molecular Aspects of Haematological Disorders |
| Year(s) Of Engagement Activity | 2016 |
| Description | MP and MSP Visit to Research Institute |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Invited to take part in an informal discussion/ presentation hosted by the British Heart Foundation in Scotland with local MPs and MSPs regarding current funding and types of research being done in Glasgow. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Medical Research Scotland Meet the Researcher Events in Dundee & Glasgow Science Centres |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Members of our group including the PDRA (JC) on the award participated in interactive workshops at the Dundee and Glasgow Science Centres for 5th and 6th secondary school pupils focusing on the Hygiene Hypothesis and therapeutic potential of parasitic worm products, and drugs based on these, in inflammatory disease and potentially on life/healthspan. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Public engagement |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | We and our group members have been involved in Explorathon events and organised interactive workshops during "Science Weeks", for example at SU and the Glasgow Science Centre, the latter focusing on a 'Drugs from Bugs, ask Dr. Worm' event, designed to involve both children and parents in our research. Relating to this, further interaction with the public is encouraged by our ES-62 website (ES62.webstarts.com) and Facebook page ("Drugs from Bugs"), which focus on educational and translational aspects of research employing parasitic worms and we are scheduled to provide our interactive workshop to local primary 4/5 school children in April 2016. |
| Year(s) Of Engagement Activity | 2014,2015 |
| URL | http://ES62.webstarts.com |
| Description | STEM Week activity at local primary school |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | I attend a local primary school during national STEM week to talk about my work and career with pupils and to run science activities related to our research |
| Year(s) Of Engagement Activity | 2016,2017,2018 |
| Description | School workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | We and our group members are active in interacting with the public via our ES-62 website (ES62.webstarts.com), Facebook page ("Drugs from Bugs") and @HarnettLabsTwitter account, all of which focus on educational and translational aspects of research employing parasitic worms in inflammatory disease. Moreover, we presented our interactive workshop 'Drugs from Bugs, ask Dr. Worm' to >50 local primary 4/5 school children (May 2016) |
| Year(s) Of Engagement Activity | 2016 |
| Description | South East Scotland Blood Club meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Health professionals |
| Results and Impact | talk opened up discussion |
| Year(s) Of Engagement Activity | 2014 |
| Description | Stem cell symposium Cambridge |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | talk and discussion improved collaboration |
| Year(s) Of Engagement Activity | 2014 |
| Description | Talk - MD Anderson Centre, Houston, USA |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Lecture as part of the Haematology Grand Round at the MD Anderson Centre, Houston |
| Year(s) Of Engagement Activity | 2016 |
| Description | Till and McCulloch meeting, Toronto |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Guest speaker at the Till and McCulloch meeting, Toronto, Canada |
| Year(s) Of Engagement Activity | 2015 |